Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography

Luzerner Kantonsspital

Status: Completed

Conditions: Antineoplastic Agents; Heart Failure, Congestive

Treatments: Device: Doppler-echocardiography and acoustic cardiography

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00541801

Audicor-Oncology

Details and patient eligibility

About

In this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to Doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.

Full description

Patients receiving cardio-toxic cytostatic agents are examined by Doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. Doppler-echocardiography measures ejection fraction, TDI, speckle tracking, and further parameters. Acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Heart function as assessed by Doppler-echocardiography is then compared to the heart function as assessed by Audicor ECG.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with malignant disease with scheduled anthracycline and trastuzumab therapy

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)